vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and Xos, Inc. (XOS). Click either name above to swap in a different company.
Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $5.2M, roughly 1.8× Xos, Inc.). Xos, Inc. runs the higher net margin — -186.8% vs -234.3%, a 47.5% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs -54.5%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs -35.7%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
Xos, Inc. is an American manufacturer of commercial electric vehicles (EVs) and mobile EV chargers.
FHTX vs XOS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $5.2M |
| Net Profit | $-21.7M | $-9.8M |
| Gross Margin | — | -50.5% |
| Operating Margin | -258.2% | -186.6% |
| Net Margin | -234.3% | -186.8% |
| Revenue YoY | 223.8% | -54.5% |
| Net Profit YoY | -11.1% | 48.6% |
| EPS (diluted) | $-0.35 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $5.2M | ||
| Q3 25 | $8.2M | $16.5M | ||
| Q2 25 | $7.6M | $18.4M | ||
| Q1 25 | $6.0M | $5.9M | ||
| Q4 24 | $2.9M | $11.5M | ||
| Q3 24 | $7.8M | $15.8M | ||
| Q2 24 | $6.9M | $15.5M | ||
| Q1 24 | $5.0M | $12.6M |
| Q4 25 | $-21.7M | $-9.8M | ||
| Q3 25 | $-15.8M | $2.1M | ||
| Q2 25 | $-17.9M | $-7.5M | ||
| Q1 25 | $-18.8M | $-10.2M | ||
| Q4 24 | $-19.5M | $-19.0M | ||
| Q3 24 | $-19.1M | $-10.5M | ||
| Q2 24 | $-23.0M | $-9.7M | ||
| Q1 24 | $-25.0M | $-11.0M |
| Q4 25 | — | -50.5% | ||
| Q3 25 | — | 15.3% | ||
| Q2 25 | — | 8.8% | ||
| Q1 25 | — | 20.6% | ||
| Q4 24 | — | -32.4% | ||
| Q3 24 | — | 18.1% | ||
| Q2 24 | — | 13.1% | ||
| Q1 24 | — | 22.1% |
| Q4 25 | -258.2% | -186.6% | ||
| Q3 25 | -226.9% | -42.4% | ||
| Q2 25 | -279.2% | -38.5% | ||
| Q1 25 | -385.0% | -157.7% | ||
| Q4 24 | -840.5% | -127.0% | ||
| Q3 24 | -305.5% | -61.4% | ||
| Q2 24 | -386.6% | -73.2% | ||
| Q1 24 | -558.3% | -81.1% |
| Q4 25 | -234.3% | -186.8% | ||
| Q3 25 | -194.4% | 12.9% | ||
| Q2 25 | -237.3% | -40.8% | ||
| Q1 25 | -316.4% | -173.3% | ||
| Q4 24 | -682.9% | -165.4% | ||
| Q3 24 | -244.9% | -66.6% | ||
| Q2 24 | -333.6% | -62.2% | ||
| Q1 24 | -495.4% | -87.1% |
| Q4 25 | $-0.35 | $-0.76 | ||
| Q3 25 | $-0.25 | $0.22 | ||
| Q2 25 | $-0.28 | $-0.91 | ||
| Q1 25 | $-0.30 | $-1.26 | ||
| Q4 24 | $-0.23 | $-2.34 | ||
| Q3 24 | $-0.31 | $-1.32 | ||
| Q2 24 | $-0.45 | $-1.23 | ||
| Q1 24 | $-0.59 | $-1.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $14.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $23.3M |
| Total Assets | $198.1M | $60.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $14.0M | ||
| Q3 25 | $89.3M | $14.1M | ||
| Q2 25 | $72.6M | $8.8M | ||
| Q1 25 | $61.0M | $4.8M | ||
| Q4 24 | $55.5M | $11.0M | ||
| Q3 24 | $57.7M | $8.4M | ||
| Q2 24 | $138.9M | $19.7M | ||
| Q1 24 | $79.3M | $46.2M |
| Q4 25 | $-108.5M | $23.3M | ||
| Q3 25 | $-89.7M | $31.1M | ||
| Q2 25 | $-76.7M | $18.3M | ||
| Q1 25 | $-61.7M | $24.8M | ||
| Q4 24 | $-45.5M | $33.6M | ||
| Q3 24 | $-28.3M | $50.8M | ||
| Q2 24 | $-14.3M | $59.2M | ||
| Q1 24 | $-97.5M | $67.8M |
| Q4 25 | $198.1M | $60.4M | ||
| Q3 25 | $205.0M | $73.8M | ||
| Q2 25 | $226.2M | $80.3M | ||
| Q1 25 | $258.7M | $87.7M | ||
| Q4 24 | $284.0M | $98.3M | ||
| Q3 24 | $308.4M | $120.5M | ||
| Q2 24 | $328.6M | $123.4M | ||
| Q1 24 | $255.0M | $135.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $2.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $2.4M | ||
| Q3 25 | $-18.9M | $3.1M | ||
| Q2 25 | $-21.0M | $4.6M | ||
| Q1 25 | $-24.0M | $-4.8M | ||
| Q4 24 | $-24.5M | $3.3M | ||
| Q3 24 | $-21.0M | $-11.5M | ||
| Q2 24 | $-25.5M | $-26.0M | ||
| Q1 24 | $-29.3M | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-21.0M | — | ||
| Q1 25 | $-24.0M | — | ||
| Q4 24 | $-25.0M | — | ||
| Q3 24 | $-21.3M | $-11.7M | ||
| Q2 24 | $-25.6M | $-26.1M | ||
| Q1 24 | $-29.4M | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -278.2% | — | ||
| Q1 25 | -403.2% | — | ||
| Q4 24 | -875.3% | — | ||
| Q3 24 | -273.0% | -73.9% | ||
| Q2 24 | -371.0% | -168.1% | ||
| Q1 24 | -583.1% | -115.7% |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.3% | 0.0% | ||
| Q1 25 | 0.5% | 0.0% | ||
| Q4 24 | 16.8% | 0.0% | ||
| Q3 24 | 4.0% | 0.9% | ||
| Q2 24 | 0.2% | 0.8% | ||
| Q1 24 | 2.0% | 0.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.45× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
